Provided by Tiger Fintech (Singapore) Pte. Ltd.

Werewolf Therapeutics, Inc.

1.19
-0.0500-4.03%
Volume:101.44K
Turnover:124.57K
Market Cap:53.03M
PE:-0.78
High:1.28
Open:1.20
Low:1.18
Close:1.24
Loading ...

Innovative Cytokine Immunotherapy: Werewolf Therapeutics’ Pioneering Approach and Promising Pipeline

TIPRANKS
·
19 Nov 2024

Buy Rating for Werewolf Therapeutics: Strong Financial Position and Promising Pipeline

TIPRANKS
·
11 Nov 2024

Werewolf Therapeutics presents preclinical, clinical data on WTX-330

TIPRANKS
·
07 Nov 2024

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire
·
07 Nov 2024

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
07 Nov 2024

Werewolf Therapeutics: as of Sept 30, 2024, Cash and Cash Equivalents Were $122.8 Mln

THOMSON REUTERS
·
07 Nov 2024

Werewolf Therapeutics: Updated Cash Guidance Provides Runway Through at Least Q2 of 2026

THOMSON REUTERS
·
07 Nov 2024

Werewolf Therapeutics Q3 Basic EPS USD -0.38

THOMSON REUTERS
·
07 Nov 2024

Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases

THOMSON REUTERS
·
31 Oct 2024

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

GlobeNewswire
·
31 Oct 2024

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire
·
04 Oct 2024

Werewolf Therapeutics: A Buy Rating with Strong Upside Potential Amidst Market Pullbacks

TIPRANKS
·
10 Sep 2024